Bayer Increases Chinese Presence With Topsun Cough/Cold Buy
This article was originally published in PharmAsia News
Executive Summary
Bayer expects its purchase of Topsun Science & Technology's nonprescription cough and cold portfolio to "substantially increase Bayer Consumer Care's presence in China, one of the fastest growing OTC markets in the world," the firm states Oct. 25